N/A N=54 Randomized Double-blind Treatment

Impact of Vitamin D on Diabetic Kidney Disease in African Americans

Diabetic Kidney Disease

Bottom Line

View on ClinicalTrials.gov: NCT01214356 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Oct 2018

Primary outcome: Primary: Change in Urinary Albumin:Creatinine Ratio (ACR) — -52.55555556; 46.44444444 ratio

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Vitamin D3 (Dietary_supplement)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Medical University of South Carolina
Primary completion: Jul 2013

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Urinary Albumin:Creatinine Ratio (ACR)	-52.55555556; 46.44444444	—
SECONDARY Decrease in Estimated Glomerular Filtration Rate (eGFR)	—	—

Summary

This purpose of this project is to evaluate the effectiveness of vitamin D supplementation over 12 months in vitamin D deficient African American adults with type 2 diabetes.

Eligibility Criteria

Inclusion Criteria

African American race
Diagnosis of Type 2 Diabetes
Stage 1 or 2 Kidney Disease with detectable microalbuminuria >4.0 (mg/g) 25(OH)D level Stage 3 Kidney Disease, or history of dialysis, kidney transplantation or nephrolithiasis
Unable to provide informed consent or contact information
Pre-existing calcium or parathyroid condition, including serum calcium >10.2 mg/dL
Sarcoidosis, active tuberculosis, or malignancy
Known hypersensitivity to vitamin D or any of its analogues and derivatives
Current pregnancy or planning to become pregnant in next 15 months

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01214356). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.